169 related articles for article (PubMed ID: 34675191)
1. Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype.
Deng J; Tian AL; Pan H; Sauvat A; Leduc M; Liu P; Zhao L; Zhang S; Chen H; Taly V; Laurent-Puig P; Senovilla L; Li Y; Kroemer G; Kepp O
Cell Death Dis; 2021 Oct; 12(11):978. PubMed ID: 34675191
[TBL] [Abstract][Full Text] [Related]
2. Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer.
Källberg J; Harrison A; March V; Bērziņa S; Nemazanyy I; Kepp O; Kroemer G; Mouillet-Richard S; Laurent-Puig P; Taly V; Xiao W
Cell Death Dis; 2023 May; 14(5):306. PubMed ID: 37142595
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration.
Bastin J; Sroussi M; Nemazanyy I; Laurent-Puig P; Mouillet-Richard S; Djouadi F
J Transl Med; 2023 Aug; 21(1):522. PubMed ID: 37533102
[TBL] [Abstract][Full Text] [Related]
4. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
[No Abstract] [Full Text] [Related]
5. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK.
Chen RM; Chiou YS; Chong QY; Poh HM; Tan TZ; Zhang MY; Ma L; Zhu T; Pandey V; Basappa ; Kumar AP; Lobie PE
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835445
[TBL] [Abstract][Full Text] [Related]
7. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.
Linnekamp JF; Hooff SRV; Prasetyanti PR; Kandimalla R; Buikhuisen JY; Fessler E; Ramesh P; Lee KAST; Bochove GGW; de Jong JH; Cameron K; Leersum RV; Rodermond HM; Franitza M; Nürnberg P; Mangiapane LR; Wang X; Clevers H; Vermeulen L; Stassi G; Medema JP
Cell Death Differ; 2018 Mar; 25(3):616-633. PubMed ID: 29305587
[TBL] [Abstract][Full Text] [Related]
8. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
[TBL] [Abstract][Full Text] [Related]
9. Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).
Ubink I; Bloemendal HJ; Elias SG; Brink MA; Schwartz MP; Holierhoek YCW; Verheijen PM; Boerman AW; Mathijssen RHJ; de Leng WWJ; de Weger RA; van Grevenstein WMU; Koopman M; Lolkema MP; Kranenburg O; Borel Rinkes IHM
BMC Cancer; 2017 Apr; 17(1):282. PubMed ID: 28424071
[TBL] [Abstract][Full Text] [Related]
10. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
[TBL] [Abstract][Full Text] [Related]
11. Mithramycin A Inhibits Colorectal Cancer Growth by Targeting Cancer Stem Cells.
Quarni W; Dutta R; Green R; Katiri S; Patel B; Mohapatra SS; Mohapatra S
Sci Rep; 2019 Oct; 9(1):15202. PubMed ID: 31645574
[TBL] [Abstract][Full Text] [Related]
12. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer.
Lim SH; Cho HJ; Kim KM; Lim HY; Kang WK; Lee J; Park YS; Kim HC; Kim ST
Oncol Res; 2023; 31(6):855-866. PubMed ID: 37744267
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic subtypes predict outcomes in colorectal cancer.
Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
[TBL] [Abstract][Full Text] [Related]
15. Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.
Pivonello C; Patalano R; Solari D; Auriemma RS; Frio F; Vitulli F; Grasso LFS; Di Cera M; De Martino MC; Cavallo LM; Cappabianca P; Colao A; Pivonello R
Endocrine; 2018 Dec; 62(3):663-680. PubMed ID: 30066286
[TBL] [Abstract][Full Text] [Related]
16. Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia.
Nair RR; Piktel D; Geldenhuys WJ; Gibson LF
Leuk Res; 2018 Sep; 72():59-66. PubMed ID: 30103201
[TBL] [Abstract][Full Text] [Related]
17. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases.
Ubink I; van Eden WJ; Snaebjornsson P; Kok NFM; van Kuik J; van Grevenstein WMU; Laclé MM; Sanders J; Fijneman RJA; Elias SG; Borel Rinkes IHM; Aalbers AGJ; Kranenburg O
Br J Surg; 2018 Jan; 105(2):e204-e211. PubMed ID: 29341165
[TBL] [Abstract][Full Text] [Related]
18. Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in
Stahler A; Hoppe B; Na IK; Keilholz L; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Goekkurt E; Kasper S; Kind AJ; Kurreck A; Alig AHS; Held S; Reinacher-Schick A; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
J Clin Oncol; 2023 Jun; 41(16):2975-2987. PubMed ID: 37018649
[TBL] [Abstract][Full Text] [Related]
19. Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer.
Buikhuisen JY; Gomez Barila PM; Cameron K; Suijkerbuijk SJE; Lieftink C; di Franco S; Krotenberg Garcia A; Uceda Castro R; Lenos KJ; Nijman LE; Torang A; Longobardi C; de Jong JH; Dekker D; Stassi G; Vermeulen L; Beijersbergen RL; van Rheenen J; Huveneers S; Medema JP
J Exp Clin Cancer Res; 2023 Mar; 42(1):56. PubMed ID: 36869386
[TBL] [Abstract][Full Text] [Related]
20. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.
Curigliano G; Martin M; Jhaveri K; Beck JT; Tortora G; Fazio N; Maur M; Hubner RA; Lahner H; Donnet V; Ajipa O; Li Z; Blumenstein L; Andre F
Eur J Cancer; 2021 Jul; 151():49-62. PubMed ID: 33964572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
